Microbiome research company Clinical Microbiomics has announced the acquisition of MS-Omics, a Danish metabolomics provider.
With this acquisition, Clinical Microbiomics seeks to add leading expertise in metabolite profiling from MS-Omics to further advance its systems biology platform and help researchers worldwide understand the microbiome and how to impact health and disease.
Anders Grøn, CEO at Clinical Microbiomics, commented: "There is an unmet need in the microbiome field for better solutions to integrate microbiome and metabolome data. This demands a truly interdisciplinary approach – one that is made possible through this acquisition. We’re excited to engage with our network of researchers around the world to bring the new platform and services to work.”
Microbiome science is widely proposed as the next frontier in addressing our most urgent health challenges and organisations worldwide are exploring this potential by developing nutritional products, live-biotherapeutics, and diagnostic tests.
The microbiome impacts health via the metabolites that it produces or modifies. This includes secondary microbial metabolites, conversion of food and drugs, and human-derived metabolites such as bile acids. In fact, the microbiome is a major source of variation in the human metabolome.
This transaction is a big milestone for our companies. It is a result of a strategic dialogue where it became clear that together we would be uniquely positioned to address microbiome research questions across the field
This interplay is too complex to understand from the microbiome functional potential or the metabolome alone. Clinical Microbiomics is utilising advanced bioinformatics and systems biology to integrate the two disciplines paving the way for new innovations.
Morten Danielsen, CEO at MS-Omics, commented: “This transaction is a big milestone for our companies. It is a result of a strategic dialogue where it became clear that together we would be uniquely positioned to address microbiome research questions across the field. Together, we will be in position to offer a differentiated portfolio of services, lead the way with innovative concepts designed specifically for the fast-growing microbiome field, and benefit from improved sales coverage around the world. ”
Earlier this month, Clinical Microbiomics announced the finalisation of a €10 million investment from Seventure Partners’ “Health for Life Capital II” fund.